Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRY1 | Q16526 | 3/20 | 0.37 |
| ▸ | CRY2 | Q49AN0 | 3/20 | 0.37 |
| ▸ | PER2 | O15055 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15745493 | 0.88 | CRY1 (0.38) | CRY1CRY2PER2OPRM1OPRD1 | |
| SCHEMBL23613031 | 0.85 | CRY1 (0.42) | CRY1CRY2PER2TSHR | |
| SCHEMBL23613186 | 0.82 | — | — | |
| SCHEMBL15139521 | 0.80 | L3MBTL1 (0.35) | CRY1CRY2PER2 | |
| SCHEMBL16261610 | 0.79 | CA1 (0.46) | CRY1CRY2PER2OPRM1OPRD1 | |
| SCHEMBL15746837 | 0.74 | ADH1C (0.37) | CRY1CRY2PER2OPRM1OPRD1 | |
| SCHEMBL14577415 | 0.74 | PER2 (0.34) | CRY1CRY2PER2TSHR | |
| SCHEMBL18611360 | 0.74 | CRY1 (0.35) | CRY1CRY2PER2 | |
| SCHEMBL23792436 | 0.72 | ALDH1A1 (0.30) | — | |
| SCHEMBL21789768 | 0.72 | LMNA (0.33) | CRY1CRY2PER2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20220396563-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2022-12-15 | — | — | US | disclosed |
| US-11084800-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-20200071301-A1 | Aryi, Heteroaryl, and Heterocyclic Pharmaceutical Compounds for Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071301-A1 | Aryi, Heteroaryl, and Heterocyclic Pharmaceutical Compounds for Treatment of Medical Disorders | CFD, TFPI, CFH | CRY1 3563/4885CRY2 4326/4885PER2 3468/4885 |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | CFD, TFPI, CFH | CRY1 3224/4885CRY2 3878/4885PER2 2895/4885 |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | CRY1 3224/4885CRY2 3878/4885PER2 2895/4885 |
| US-20220396563-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | CRY1 3224/4885CRY2 3878/4885PER2 2895/4885 |
| US-11084800-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | CFD, TFPI, CFH | CRY1 3224/4885CRY2 3878/4885PER2 2895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.